* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company imports and sells medicines.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 51.8% | 46.1% | 50.4% | 49.0% | 56.1% | 57.0% | 49.2% |
| EBITDA Margin | 31.6% | 21.5% | 31.3% | 23.0% | 37.5% | 24.3% | 17.7% |
| EBITDAR | 1,693 | 1,229 | 2,248 | 1,999 | 3,534 | 1,977 | 1,528 |
| EBITDAR Margin | 32.7% | 23.2% | 32.8% | 24.2% | 38.5% | 25.2% | 19.0% |
| EBIT Margin | 31.6% | 21.5% | 31.3% | 23.0% | 37.5% | 24.3% | 17.7% |
| Net Profit Margin | 31.0% | 21.5% | 28.2% | 19.6% | 34.2% | 19.0% | 14.0% |
| Operating Expense % of Sales | 20.2% | 24.6% | 19.1% | 26.1% | 18.7% | 32.7% | 31.5% |
| Returns | |||||||
| Return on Assets (ROA) | 39.5% | 22.3% | 33.9% | 23.1% | 41.3% | 21.7% | 16.0% |
| Return on Equity (ROE) | 45.9% | 32.7% | 44.6% | 32.2% | 46.8% | 22.4% | 17.9% |
| ROIC [EBIT / Invested Capital] | 49.2% | 34.1% | 49.8% | 32.5% | 49.0% | 29.1% | 22.5% |
| Leverage & debt balances | |||||||
| Debt-to-Assets | 7.2% | 6.5% | 6.6% | 16.5% | 4.9% | 0.0% | 2.1% |
| Debt-to-Equity | 0.08x | 0.10x | 0.09x | 0.23x | 0.06x | 0.00x | 0.02x |
| Debt-to-EBITDA | 0.18x | 0.29x | 0.17x | 0.61x | 0.11x | 0.00x | 0.10x |
| Equity-to-Assets | 86.1% | 68.4% | 76.1% | 71.6% | 88.1% | 96.8% | 89.3% |
| Net Debt | -167 | -149 | -30 | 809 | 305 | -121 | 40 |
| Cash & Equivalents | 461 | 482 | 405 | 351 | 66 | 121 | 109 |
| Total Debt | 294 | 333 | 374 | 1,159 | 371 | N/A | 150 |
| Liquidity & working capital | |||||||
| Current Ratio | 7.14x | 3.04x | 4.07x | 2.96x | 7.21x | 23.72x | 7.19x |
| Quick Ratio | 7.14x | 1.61x | 2.34x | 2.96x | 7.21x | 23.72x | 7.19x |
| Cash Ratio | 0.88x | 0.31x | 0.31x | 0.18x | 0.08x | 0.54x | 0.14x |
| Total Current Assets | 3,727 | 4,758 | 5,357 | 5,763 | 6,231 | 5,290 | 5,456 |
| Total Current Liabilities | 522 | 1,566 | 1,317 | 1,947 | 865 | 223 | 759 |
| Inventory | N/A | 2,236 | 2,283 | N/A | N/A | N/A | N/A |
| Trade Receivables | 1,209 | 1,444 | 1,970 | 2,033 | 3,451 | 3,007 | 2,897 |
| Trade Payables | 265 | 1,265 | 986 | 831 | 537 | 221 | 610 |
| Net Working Capital | 3,205 | 3,192 | 4,041 | 3,816 | 5,367 | 5,067 | 4,696 |
| Net Working Capital % of Revenue | 61.9% | 60.4% | 58.9% | 46.2% | 58.4% | 64.7% | 58.4% |
| Trade Working Capital | 944 | 2,415 | 3,267 | 1,202 | 2,914 | 2,786 | 2,287 |
| Trade Working Capital % of Revenue | 18.2% | 45.7% | 47.7% | 14.6% | 31.7% | 35.6% | 28.4% |
| Change in Trade Working Capital | N/A | 1,471 | 851 | -2,065 | 1,712 | -128 | -499 |
| Turnover & efficiency | |||||||
| Inventory Turnover | N/A | 1.27x | 1.49x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 286.5 | 245.0 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 4.28x | 3.66x | 3.48x | 4.06x | 2.66x | 2.60x | 2.78x |
| Days Sales Outstanding (DSO) | 85.2 | 99.7 | 104.9 | 89.9 | 137.1 | 140.2 | 131.4 |
| Payables Turnover | 9.42x | 2.25x | 3.45x | 5.06x | 7.52x | 15.27x | 6.70x |
| Days Payable Outstanding (DPO) | 38.7 | 162.0 | 105.9 | 72.1 | 48.6 | 23.9 | 54.5 |
| Cash Conversion Cycle | 46.5 days | 224.1 days | 244.1 days | 17.8 days | 88.5 days | 116.3 days | 76.9 days |
| Asset Turnover | 1.27x | 1.04x | 1.20x | 1.18x | 1.21x | 1.14x | 1.14x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | 1,464 | 1,130 | 927 | 242 | 1,928 | 2,056 | 1,304 |
| Free Cash Flow (OCF − Capex proxy) | 187 | 1,130 | 927 | 156 | 1,928 | 1,967 | 1,283 |
| Cash Conversion (OCF / EBITDA) | 89.3% | 99.2% | 43.2% | 12.8% | 56.0% | 108.2% | 91.5% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →